COMMUNIQUÉS West-GlobeNewswire

Correction: iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering
28/07/2025
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects the version issued on July 24, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is [...]
Cellectis publiera ses résultats financiers du deuxième trimestre 2025 le 4 août 2025
28/07/2025
NEW YORK, 28 juill. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome [...]
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
28/07/2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results
28/07/2025
Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2 nd Highest in the Company’s History International [...]
Correction: iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering
28/07/2025
WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects a version issued on July 25, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not [...]
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025
28/07/2025
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its [...]
Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status
28/07/2025
CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from the staff of the Nasdaq Listing Qualifications office of the [...]
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
28/07/2025
WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today welcomes the White House’s release of “Winning the Race: America’s AI Action Plan”, issued July [...]
Press release: Transparency Notification from Shareholders
28/07/2025
Transparency Notification from Shareholders Ghent, Belgium – 28 July 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
EssilorLuxottica: Résultats T2/S1 2025 - Solide croissance du chiffre d'affaires à 7,3 % au T2 et au S1, nouvelle accélération sur les lunettes avec IA
28/07/2025
Solide croissance du chiffre d'affaires à 7,3 % au T2 et au S1 Nouvelle accélération sur les lunettes avec IA Croissance du chiffre d'affaires du Groupe à 7,3 % au T2 et au S1 (à taux de change constants 1 ) L'Amérique [...]
EssilorLuxottica: Q2/H1 2025 Results - Sound revenue growth at 7.3% in Q2 and H1, AI glasses speeding up further
28/07/2025
Sound revenue growth at 7.3% in Q2 and H1 AI glasses speeding up further Group’s revenue growing 7.3% in both Q2 and H1 (constant exchange rates 1 ) North America accelerating in PS, DTC keeping a solid growth pace EMEA [...]
Floe Health Launches to Power Intelligence at Every Patient Touchpoint
28/07/2025
San Francisco, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Floe Health , a new Healthcare AI company focused on solving the hidden operational gaps in healthcare, today announced the official launch of its platform built to [...]
Can-Fite Announces Up To $15.0 Million Public Offering
28/07/2025
$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma [...]
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
28/07/2025
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers [...]
ProQR Announces Upcoming Presentation at RNA Editing Summit
28/07/2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
28/07/2025
Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between [...]
IMUNON Announces Stock Dividend Boosting Shareholder Value
28/07/2025
Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a [...]
NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025
28/07/2025
Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration. Troculeucel was [...]
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
28/07/2025
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) (" Supernus ", and the "Company"), today announced that the required waiting period under the Hart- [...]

Pages